Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 59

1.

Electroencephalographic power spectral density profile of the orexin receptor antagonist suvorexant in patients with primary insomnia and healthy subjects.

Ma J, Svetnik V, Snyder E, Lines C, Roth T, Herring WJ.

Sleep. 2014 Oct 1;37(10):1609-19. doi: 10.5665/sleep.4068.

2.

Postoperative sleep disturbances after zolpidem treatment in fast-track hip and knee replacement.

Krenk L, Jennum P, Kehlet H.

J Clin Sleep Med. 2014 Mar 15;10(3):321-6. doi: 10.5664/jcsm.3540.

3.

Assessment of the abuse liability of a dual orexin receptor antagonist: a crossover study of almorexant and zolpidem in recreational drug users.

Cruz HG, Hoever P, Chakraborty B, Schoedel K, Sellers EM, Dingemanse J.

CNS Drugs. 2014 Apr;28(4):361-72. doi: 10.1007/s40263-014-0150-x.

PMID:
24627301
4.

National use of prescription medications for insomnia: NHANES 1999-2010.

Bertisch SM, Herzig SJ, Winkelman JW, Buettner C.

Sleep. 2014 Feb 1;37(2):343-9. doi: 10.5665/sleep.3410.

5.

Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults.

Puustinen J, Lähteenmäki R, Polo-Kantola P, Salo P, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä SL.

Eur J Clin Pharmacol. 2014 Mar;70(3):319-29. doi: 10.1007/s00228-013-1613-6. Epub 2013 Dec 12.

PMID:
24337417
6.

Melatonin for sedative withdrawal in older patients with primary insomnia: a randomized double-blind placebo-controlled trial.

Lähteenmäki R, Puustinen J, Vahlberg T, Lyles A, Neuvonen PJ, Partinen M, Räihä I, Kivelä SL.

Br J Clin Pharmacol. 2014 Jun;77(6):975-85. doi: 10.1111/bcp.12294.

PMID:
24286360
7.

Insomnia and associated factors among anaesthetists in Hong Kong.

Lee KY, Chen PP, Tse LA.

Anaesth Intensive Care. 2013 Nov;41(6):750-8.

PMID:
24180716
8.
9.

Effectiveness of non-benzodiazepine hypnotics in treatment of adult insomnia: meta-analysis of data submitted to the Food and Drug Administration.

Huedo-Medina TB, Kirsch I, Middlemass J, Klonizakis M, Siriwardena AN.

BMJ. 2012 Dec 17;345:e8343. doi: 10.1136/bmj.e8343. Review.

10.

Efficacy of eight months of nightly zolpidem: a prospective placebo-controlled study.

Randall S, Roehrs TA, Roth T.

Sleep. 2012 Nov 1;35(11):1551-7. doi: 10.5665/sleep.2208.

11.

A randomized placebo-controlled polysomnographic study of eszopiclone in Japanese patients with primary insomnia.

Uchimura N, Kamijo A, Kuwahara H, Uchiyama M, Shimizu T, Chiba S, Inoue Y.

Sleep Med. 2012 Dec;13(10):1247-53. doi: 10.1016/j.sleep.2012.08.015. Epub 2012 Oct 11.

PMID:
23063301
12.

Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years.

Lyseng-Williamson KA.

Drugs Aging. 2012 Nov;29(11):911-23. doi: 10.1007/s40266-012-0018-z. Review.

PMID:
23044640
13.

A comparison between acupuncture versus zolpidem in the treatment of primary insomnia.

Tu JH, Chung WC, Yang CY, Tzeng DS.

Asian J Psychiatr. 2012 Sep;5(3):231-5. doi: 10.1016/j.ajp.2011.12.003. Epub 2012 Jan 23.

PMID:
22981051
14.

MSLT in primary insomnia: stability and relation to nocturnal sleep.

Roehrs TA, Randall S, Harris E, Maan R, Roth T.

Sleep. 2011 Dec 1;34(12):1647-52. doi: 10.5665/sleep.1426.

15.

EEG spectral power density profiles during NREM sleep for gaboxadol and zolpidem in patients with primary insomnia.

Lundahl J, Deacon S, Maurice D, Staner L.

J Psychopharmacol. 2012 Aug;26(8):1081-7. doi: 10.1177/0269881111424457. Epub 2011 Nov 5.

PMID:
22057018
16.

Twelve months of nightly zolpidem does not lead to rebound insomnia or withdrawal symptoms: a prospective placebo-controlled study.

Roehrs TA, Randall S, Harris E, Maan R, Roth T.

J Psychopharmacol. 2012 Aug;26(8):1088-95. doi: 10.1177/0269881111424455. Epub 2011 Oct 16.

18.

Twelve months of nightly zolpidem does not lead to dose escalation: a prospective placebo-controlled study.

Roehrs TA, Randall S, Harris E, Maan R, Roth T.

Sleep. 2011 Feb 1;34(2):207-12.

19.

Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.

Fava M, Asnis GM, Shrivastava RK, Lydiard B, Bastani B, Sheehan DV, Roth T.

J Clin Psychiatry. 2011 Jul;72(7):914-28. doi: 10.4088/JCP.09m05571gry. Epub 2010 Dec 28.

PMID:
21208597
20.

Sublingual zolpidem in early onset of sleep compared to oral zolpidem: polysomnographic study in patients with primary insomnia.

Staner C, Joly F, Jacquot N, Vlasova ID, Nehlin M, Lundqvist T, Edenius C, Staner L.

Curr Med Res Opin. 2010 Jun;26(6):1423-31. doi: 10.1185/03007991003788225.

PMID:
20397964
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk